>
Antigen, Antibodies, ELISA, Western Blot >
Primary Antibody >
Monoclonal Antibodies >
PIM1 / Pim-1 Antibody (clone 2C9)Brand |
Leading Biology | Catalog Number |
AMM02016G |
Product Type |
Monoclonal Antibodies | Field of Research |
|
Product Overview |
We constantly strive to ensure we provide our customers with the best antibodies. As a result of this work we offer this antibody in purified format.
We are in the process of updating our datasheets. If you have any questions regarding this update, please feel free to contact our technical support team.
This product is a high quality PIM1 / Pim-1 Antibody (clone 2C9).
|
||
Molecular Weight |
45kDa
|
||
Cellular Localization |
Antigen Cellular Localization:
Isoform 2: Cytoplasm. Nucleus.
|
||
Host |
Mouse
|
||
Species Reactivity |
Human
|
||
Target |
Human PIM1
|
||
Clone |
2C9
|
||
GeneID |
|||
UniProt ID |
|||
Function |
Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl- X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post- translational levels. Phosphorylation of CDKN1B,induces 14-3-3- proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.
|
||
Summary |
Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl- X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post- translational levels. Phosphorylation of CDKN1B,induces 14-3-3- proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.
|
||
Storage & Stability |
Store at +4°C short term. For long-term storage, aliquot and store at -20°C or below. Stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles.
|
||
Applications |
WB, IHC-P, E
|
||
Dilution |
IHC-P (5 μg/ml)
|
||
Images |
Anti-PIM1 antibody IHC of human adrenal. |
||
Specification |
|||
Quantity |
|
Select | Brand | Catalog No. | Product Name | Pack Size | Type | Field of Research | Specification | Quantity | Price(USD) | |
1 | Leading Biology | AMM07977G | SPRY1 / Sprouty 1 Antibody (clone 3H4) | 50 μg | Monoclonal Antibodies |
|
$545.00 | Add Ask | ||
2 | Leading Biology | AMM00137G | CD79a (B-Cell Marker) Antibody - With BSA and Azide | 50 ug | Monoclonal Antibodies |
|
$395.00 | Add Ask | ||
3 | Leading Biology | APG02467G | CCK4 / PTK7 Antibody (clone 4F9) | 50 μl | Monoclonal Antibodies |
|
$495.00 | Add Ask | ||
4 | Leading Biology | AMM05365G | DC-SIGN Antibody [5D7] | 0.1 mg | Monoclonal Antibodies |
|
$695.00 | Add Ask | ||
5 | Leading Biology | AMM01402G | Vimentin (Mesenchymal Cell Marker) Antibody - With BSA and Azide | 50 ug | Monoclonal Antibodies |
|
$395.00 | Add Ask | ||
6 | Leading Biology | APR08280G | LTA4H / LTA4 Antibody (clone 9G8) | 50 μl | Monoclonal Antibodies |
|
$495.00 | Add Ask |
Complete this form and click send to ask us a question, request a quote or simply say hello.
You have 0 item in your cart
You have 0 item in your inquiry list